MALAKOFF, France --(BUSINESS WIRE)--
THERACLION (Paris:ALTHE)(Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced a commercial agreement for the installation of an Echopulse® at the London Endocrine Centre located on Harley Street in London, United Kingdom (UK). This marks the first opening of an echotherapy center for the treatment of thyroid nodules in the UK and will enable patients with benign thyroid nodules access to the benefits of this non-invasive treatment alternative to surgery.
The London Endocrine Centre, established in 2003, brings together internationally recognised endocrinologists and endocrine surgeons from major university hospitals to provide the specialised care of patients with endocrine diseases. Endocrinologists of the London Endocrine Centre have significant experience in the management of all endocrine diseases from thyroid, parathyroid, adrenal and pituitary diseases to diabetes. These specialists offer an integrated approach with a focus on early diagnosis and state of the art medical and surgical treatment according to the specific needs of each patient.
“Approximately 12,000 thyroidectomies are performed in the UK each year,” said Mike Leach, vice president, UK, Northern Europe and MEA of Theraclion. “The London Endocrine Centre is recognized as a centre of excellence across UK with highly respected and internationally recognized clinicians making it a key reference site for Theraclion.”
Fausto Palazzo MS (London), FRCS (Eng), FRCS (Gen), undertakes almost exclusively thyroid, parathyroid and adrenal surgery with one of the UK’s highest volume practices with over 350 cases per year and a personal experience of over 3000 endocrine operations. The London Endocrine Centre was founded and is headed by Dr. Paul Jenkins, MA BChir MD FRCP, Consultant Physician and Endocrinologist. Dr. Jenkins has more than 20 years of experience in practice and has published 80 peer-reviewed scientific papers in endocrinology.
“The echotherapy system significantly expands our therapeutic options for thyroid disease management,” said Mr. Palazzo. “This non-invasive option will improve our patient management since it is an outpatient procedure without general anaesthesia, without scars, and with immediate recovery post-treatment.”
David Caumartin, CEO of Theraclion, added, “It is a great endorsement of our technology that the London Endocrine Centre is using our system. Worldwide more than 20 systems are scheduled for clinical use and more than 800 treatments have been performed since launch. We are seeing a strong uptake of clinical activities in the past year. 40% of all treatments performed since the start of this technology have been done in the past 12 months. This acceleration is mainly driven by thyroid treatments: in the past 12 months 10 times more treatment have been performed compared to the same period the previous year.”
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.
Theraclion is listed on Alternext Paris
Mnemonic: ALTHE - ISIN Code: FR0010120402
(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.